{"title":"第三剂COVID-19灭活疫苗对SARS-CoV-2变体的交叉中和作用","authors":"Yuqing Li, Jiexiao He, Wenqing Liu, Runjie Qi, Jingxin Li, Fengcai Zhu","doi":"10.1080/14760584.2025.2550984","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The ongoing emergence of SARS-CoV-2 variants has raised concerns about the breadth of the immune response provided by existing vaccines.</p><p><strong>Research design and methods: </strong>In this study, participants aged 18-75 years with no prior COVID-19 infection or vaccination history were enrolled to receive the CoronaVac vaccine. The interval between the first and second vaccine doses was 28 days, while the third dose was given 6 months after the second.</p><p><strong>Results: </strong>Between February 1 to 15 February 2022, we recruited 40 eligible participants who had not received any COVID-19 vaccination and had no prior COVID-19 infection. After the third dose, neutralizing antibody levels significantly increased against the ancestral strain and certain Omicron variants (BA.1, BA.4/5, BF.7). Compared to levels observed 28 days post-second dose, neutralizing antibody levels rose further 28 days after the third dose, with the GMFI against the ancestral strain at 1.69 (95% CI: 1.27, 2.20). Among other variants, the GMFI against Omicron variants (BA.1, BA.4/5, BF.7) exceeded that for Beta and Delta, with the highest GMFI recorded for the BA.4/5 variant at 4.97 (95% CI: 3.08, 8.05).</p><p><strong>Conclusions: </strong>The necessity of the third booster dose lies in its ability to enhance the breadth of the immune response.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"24 1","pages":"840-848"},"PeriodicalIF":4.8000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cross-neutralization effect of the third dose of inactivated COVID-19 vaccine against the SARS-CoV-2 variants.\",\"authors\":\"Yuqing Li, Jiexiao He, Wenqing Liu, Runjie Qi, Jingxin Li, Fengcai Zhu\",\"doi\":\"10.1080/14760584.2025.2550984\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The ongoing emergence of SARS-CoV-2 variants has raised concerns about the breadth of the immune response provided by existing vaccines.</p><p><strong>Research design and methods: </strong>In this study, participants aged 18-75 years with no prior COVID-19 infection or vaccination history were enrolled to receive the CoronaVac vaccine. The interval between the first and second vaccine doses was 28 days, while the third dose was given 6 months after the second.</p><p><strong>Results: </strong>Between February 1 to 15 February 2022, we recruited 40 eligible participants who had not received any COVID-19 vaccination and had no prior COVID-19 infection. After the third dose, neutralizing antibody levels significantly increased against the ancestral strain and certain Omicron variants (BA.1, BA.4/5, BF.7). Compared to levels observed 28 days post-second dose, neutralizing antibody levels rose further 28 days after the third dose, with the GMFI against the ancestral strain at 1.69 (95% CI: 1.27, 2.20). Among other variants, the GMFI against Omicron variants (BA.1, BA.4/5, BF.7) exceeded that for Beta and Delta, with the highest GMFI recorded for the BA.4/5 variant at 4.97 (95% CI: 3.08, 8.05).</p><p><strong>Conclusions: </strong>The necessity of the third booster dose lies in its ability to enhance the breadth of the immune response.</p>\",\"PeriodicalId\":12326,\"journal\":{\"name\":\"Expert Review of Vaccines\",\"volume\":\"24 1\",\"pages\":\"840-848\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14760584.2025.2550984\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2025.2550984","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Cross-neutralization effect of the third dose of inactivated COVID-19 vaccine against the SARS-CoV-2 variants.
Background: The ongoing emergence of SARS-CoV-2 variants has raised concerns about the breadth of the immune response provided by existing vaccines.
Research design and methods: In this study, participants aged 18-75 years with no prior COVID-19 infection or vaccination history were enrolled to receive the CoronaVac vaccine. The interval between the first and second vaccine doses was 28 days, while the third dose was given 6 months after the second.
Results: Between February 1 to 15 February 2022, we recruited 40 eligible participants who had not received any COVID-19 vaccination and had no prior COVID-19 infection. After the third dose, neutralizing antibody levels significantly increased against the ancestral strain and certain Omicron variants (BA.1, BA.4/5, BF.7). Compared to levels observed 28 days post-second dose, neutralizing antibody levels rose further 28 days after the third dose, with the GMFI against the ancestral strain at 1.69 (95% CI: 1.27, 2.20). Among other variants, the GMFI against Omicron variants (BA.1, BA.4/5, BF.7) exceeded that for Beta and Delta, with the highest GMFI recorded for the BA.4/5 variant at 4.97 (95% CI: 3.08, 8.05).
Conclusions: The necessity of the third booster dose lies in its ability to enhance the breadth of the immune response.
期刊介绍：
Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review.
The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
